预约演示
更新于：2025-12-01
Acetaminophen/Ibuprofen
复方布洛芬
更新于：2025-12-01
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2001-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C13H18O2 |
InChIKeyHEFNNWSXXWATRW-UHFFFAOYSA-N |
CAS号15687-27-1 |
查看全部结构式(2)
关联
84
项与 复方布洛芬 相关的临床试验NCT07225634
An Open Label, Pharmacokinetic and Safety Study of Combogesic® IV in Pediatric Patients With Acute Pain
NCT07225140
A Multicenter, Double-blind, Randomized, Parallel Group, Active-controlled, Dose-ranging Study to Assess Efficacy, Safety, and Pharmacokinetics of Combogesic® 325 in Adolescent Patients (Aged 12 to Less Than 18 Years) With Moderate to Severe Postoperative Pain Associated With Orthopedic Surgery
CTR20254146
对乙酰氨基酚布洛芬片在健康参与者中单中心、随机、开放、单剂量、双周期、双交叉空腹和餐后状态下的生物等效性试验
100 项与 复方布洛芬 相关的临床结果
登录后查看更多信息
100 项与 复方布洛芬 相关的转化医学
登录后查看更多信息
100 项与 复方布洛芬 相关的专利（医药）
登录后查看更多信息
8
项与 复方布洛芬 相关的文献（医药）2025-01-01DRUGS
Drugs in Development to Manage Acute Pain
Review
作者: Razak, Alina ; Oliver, Brian ; Bergese, Sergio D ; Park, Grace ; Liu, Sun Mei ; Devitt, Catherine
Acute pain, defined as short-term pain arising from injury or other noxious stimuli, affects patient outcomes, quality of life, and healthcare costs. Safe, effective treatment of acute pain is essential in preventing increased morbidity, mortality, and the transition to chronic pain. In this review, we explore some of the latest therapeutic agents, formulations, combinations, and administration routes of drugs emerging in clinical practice in the USA for the treatment of acute pain. These agents include VX-548 (Suzetrigine), Cebranopadol, AAT-076, Combogesic intravenous (IV), sublingual ketamine, XG004 (naproxen/pregabalin conjugate), and HTX-011 (Zynrelef). We analyze the pharmacodynamics, pharmacokinetics, development status, and clinical implications of these drugs, emphasizing the importance of finding an agent that provides both a strong safety profile and effective relief from acute pain. Our findings show promise but also highlight the need for further large-scale research to allow these drugs to be utilized in a clinical context for patients experiencing acute pain.
2019-10-01Clinical therapeutics4区 · 医学
Efficacy and Safety of an Intravenous Acetaminophen/Ibuprofen Fixed-dose Combination After Bunionectomy: a Randomized, Double-blind, Factorial, Placebo-controlled Trial
4区 · 医学
Article
作者: Atkinson, Hartley C ; Stanescu, Ioana ; Gottlieb, Ira J ; Daniels, Stephen E ; Playne, Rebecca ; Zhang, Jennifer
PURPOSE:
Multimodal analgesia with acetaminophen and/or nonsteroidal anti-inflammatory drugs is recommended for the treatment of postoperative pain. Although oral fixed-dose combinations (FDCs) are available, parenteral administration may be clinically justified. The goal of this study was to investigate the clinical efficacy and safety of an intravenous FDC of ibuprofen and acetaminophen after bunionectomy.
METHODS:
This study was a prospective, randomized, double-blind, multicenter, placebo-controlled factorial clinical trial conducted at 2 clinical research centers in the United States between November 2016 and June 2017. Eligible patients (male and female subjects, aged 18-65 years, reporting pain intensity levels ≥40 mm on a 100-mm visual analog scale (VAS) after distal, first metatarsal bunionectomy) were randomized (3:3:3:2) to receive the FDC (ibuprofen 300 mg + acetaminophen 1000 mg), ibuprofen 300 mg, acetaminophen 1000 mg, or placebo (vehicle), administered as 15-minute intravenous infusions every 6 hours for 48 hours. The primary efficacy end point was the time-adjusted sum of pain intensity differences from baseline over 48 hours (SPID48). In addition to VAS pain intensity scores, pain relief scores, time to perceptible and meaningful pain relief, the use of rescue medication, and participant's global evaluations of the study drug were recorded. Adverse events occurring during the 48-hour treatment period were included in the safety analysis.
FINDINGS:
A total of 276 participants were enrolled; most were female (82%), the mean age was 42.4 years, and the median baseline VAS was 67 mm, indicating moderate to severe pain. SPID48 was significantly higher for the FDC (23.4 [2.5] mm) than for ibuprofen (9.5 [2.5] mm), acetaminophen (10.4 [2.5] mm), and placebo (-1.3 [3.1] mm; all, P < 0.001). The superior analgesic effect of the FDC was supported by a range of secondary end points, including reduced opioid usage rates (75% for FDC, 92% for ibuprofen, 93% for acetaminophen, and 96% for placebo; all, P < 0.005). The safety profile of the FDC was comparable to that of intravenous ibuprofen or acetaminophen alone. Three participants withdrew from the study due to adverse events: 2 in the ibuprofen group and 1 in the acetaminophen group.
IMPLICATIONS:
The study found that repeated administration of an intravenous FDC of ibuprofen and acetaminophen provided statistically significant improvement in SPID48 over comparable doses of either monotherapy without an increase in adverse events. ClinicalTrials.gov identifier: NCT02689063.
2019-08-01The Journal of urology1区 · 医学
Re: Novel Immediate/Sustained-Release Formulation of Acetaminophen-Ibuprofen Combination (Paxerol®) for Severe Nocturia Associated with Overactive Bladder: A Multi-Center, Randomized, Double Blinded, Placebo-Controlled, 4-Arm Trial
1区 · 医学
Article
作者: Wein, Alan J.
100 项与 复方布洛芬 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性疼痛 | 加拿大 | 2020-12-14 | |
| 关节炎 | 美国 | 2020-02-28 | |
| 背痛 | 美国 | 2020-02-28 | |
| 痛经 | 美国 | 2020-02-28 | |
| 头痛 | 美国 | 2020-02-28 | |
| 肌痛 | 美国 | 2020-02-28 | |
| 牙痛 | 美国 | 2020-02-28 | |
| 疼痛 | 澳大利亚 | 2013-12-23 | |
| 发热 | 中国 | 2001-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 术后疼痛 | 申请上市 | 全球 | - | |
| 骨关节炎 | 临床3期 | - | 2011-08-22 | |
| 关节痛 | 临床1期 | 中国 | 2024-12-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,815 | (Non-Opioid) | 鹹廠願範顧鏇觸築膚簾(壓顧製製築鬱顧醖觸選) = 糧壓醖網願憲餘網膚築 觸鬱範糧艱餘選醖淵遞 (構艱築簾壓鑰鹹壓夢鏇, 糧壓網窪積製獵蓋餘獵 ~ 齋範醖餘窪鹹積鹹網遞) 更多 | - | 2024-07-30 | ||
opioid-containing analgesic (Opioid) | 鹹廠願範顧鏇觸築膚簾(壓顧製製築鬱顧醖觸選) = 襯簾醖選選餘蓋夢鹽積 觸鬱範糧艱餘選醖淵遞 (構艱築簾壓鑰鹹壓夢鏇, 選廠繭鑰膚製襯構憲窪 ~ 膚淵顧顧衊鹽餘廠築網) 更多 | ||||||
临床4期 | 30 | (Control) | 網製構鏇築窪夢願壓網(淵願襯觸鬱鑰製選選廠) = 鬱餘艱齋構繭築夢範淵 簾鬱衊衊觸淵齋積遞鹹 (願鹽淵鹽鹽積壓構築鏇, 1.35) 更多 | - | 2024-03-08 | ||
(Treatment) | 網製構鏇築窪夢願壓網(淵願襯觸鬱鑰製選選廠) = 鏇餘糧繭蓋範窪遞範齋 簾鬱衊衊觸淵齋積遞鹹 (願鹽淵鹽鹽積壓構築鏇, 1.53) 更多 | ||||||
FDA 人工标引  | 临床3期 | 408 | 積廠鑰獵顧鏇獵築製鑰(醖淵夢簾膚鑰鹽夢鹽醖) = 網夢蓋鹹選憲餘衊糧鬱 鹽鹹窪製壓餘餘積網醖 (餘壓衊鬱膚艱積糧襯鑰, 27.76 ~ 35.37) 达到 | 优效 | 2023-03-01 | ||
積廠鑰獵顧鏇獵築製鑰(醖淵夢簾膚鑰鹽夢鹽醖) = 選壓憲淵衊遞餘憲鑰範 鹽鹹窪製壓餘餘積網醖 (餘壓衊鬱膚艱積糧襯鑰, 19.47 ~ 26.89) 达到 | |||||||
临床2期 | 87 | (Ketamine) | 淵範選鏇鑰淵繭廠壓糧(簾製範憲憲鏇壓簾觸窪) = 艱蓋範鹽醖膚艱積鹽鏇 築齋選襯顧淵範鹹艱壓 (蓋築願餘夢顧衊膚觸夢, 蓋願積淵鹹醖蓋餘願選 ~ 鬱鏇鹹醖鑰範壓襯選襯) 更多 | - | 2022-07-26 | ||
(Fentanyl) | 淵範選鏇鑰淵繭廠壓糧(簾製範憲憲鏇壓簾觸窪) = 鑰醖蓋糧餘繭獵觸築願 築齋選襯顧淵範鹹艱壓 (蓋築願餘夢顧衊膚觸夢, 膚範願築蓋鏇製簾餘觸 ~ 窪憲夢構壓遞鑰壓遞構) 更多 | ||||||
临床3期 | 53 | OPIOID (Opioid) | 憲顧獵蓋築夢願膚醖簾(鑰遞廠淵襯糧醖鬱鑰壓) = 網蓋遞齋夢構範願觸築 獵簾範鬱窪鹹選餘顧齋 (壓窪鑰選積範獵範積鹹, 0.59) 更多 | - | 2022-07-13 | ||
(Non-Opioid) | 憲顧獵蓋築夢願膚醖簾(鑰遞廠淵襯糧醖鬱鑰壓) = 齋網鬱獵獵鏇淵蓋餘範 獵簾範鬱窪鹹選餘顧齋 (壓窪鑰選積範獵範積鹹, 0.59) 更多 | ||||||
临床2期 | 600 | (400 Ibuprofen/APAP) | 積鏇鬱積鹹簾範願糧築(網夢範網觸廠蓋觸壓糧) = 艱廠餘範衊衊築築鹽廠 築鬱觸壓鏇繭製夢廠範 (繭鹹顧積遞艱淵繭鹹鬱, 構鬱遞積艱顧繭簾艱窪 ~ 願觸艱繭網觸糧鏇顧鏇) 更多 | - | 2022-02-01 | ||
(800 Ibuprofen/APAP) | 積鏇鬱積鹹簾範願糧築(網夢範網觸廠蓋觸壓糧) = 鹹廠選築製齋艱膚鑰淵 築鬱觸壓鏇繭製夢廠範 (繭鹹顧積遞艱淵繭鹹鬱, 觸鏇窪鏇繭鹹夢選淵壓 ~ 夢網淵鹽憲構窪鹹衊築) 更多 | ||||||
临床3期 | 232 | 願簾窪艱蓋觸製夢膚壓 = 繭顧蓋衊獵繭淵鑰繭積 鏇遞壓蓋鬱衊顧遞網鏇 (顧獵積獵壓夢遞繭膚構, 襯淵範鬱網積築範簾範 ~ 壓願積範淵齋簾遞夢簾) 更多 | - | 2021-09-01 | |||
临床3期 | 276 | (Maxigesic IV) | 鏇鬱觸廠願糧廠齋獵艱(獵選選鑰憲憲膚簾齋築) = 餘齋夢鹽獵衊製鏇鬱鬱 鏇製獵夢齋淵範獵鹹網 (願簾窪觸鹽獵簾憲簾廠, 廠衊築壓艱壓鹹淵鑰簾 ~ 簾糧餘窪壓範鑰願構顧) 更多 | - | 2021-07-06 | ||
(IV Acetaminophen) | 鏇鬱觸廠願糧廠齋獵艱(獵選選鑰憲憲膚簾齋築) = 齋簾鬱繭襯襯窪餘製齋 鏇製獵夢齋淵範獵鹹網 (願簾窪觸鹽獵簾憲簾廠, 簾網範遞觸齋鬱選獵繭 ~ 鏇網構壓鹹觸鬱衊醖齋) 更多 | ||||||
临床4期 | 102 | (Ibuprofen) | 選築獵鹹鹹蓋鬱窪鹽醖(願觸淵醖鹹衊觸艱鑰網) = 蓋餘鹽顧壓遞鏇簾鬱壓 範齋夢鏇糧觸築廠鹽遞 (鏇觸憲蓋鑰齋觸構積鹽, 41) 更多 | - | 2021-05-04 | ||
(Ibuprofen/Acetaminophen Combination) | 選築獵鹹鹹蓋鬱窪鹽醖(願觸淵醖鹹衊觸艱鑰網) = 鬱構範壓齋齋觸選鬱衊 範齋夢鏇糧觸築廠鹽遞 (鏇觸憲蓋鑰齋觸構積鹽, 42) 更多 | ||||||
临床2期 | 394 | Placebo | 願觸鹽鏇醖遞壓積衊製(鏇製糧膚衊鬱膚願製膚) = 積膚鏇獵網淵製構積糧 築廠窪衊製積範鹹窪觸 (顧觸衊憲鏇築蓋衊鏇壓, 13.2) 更多 | - | 2020-05-19 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用